GleamWall
中文EN

TIL Instil Bio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1789769 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY71.9%
TTM EPS YoY73.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-19.2%
ROA-10.4%
ROIC (approx.)-21.8%
Asset turnover—

Leverage & solvency

Liabilities / assets47.6%
Debt / equity0.00x
Current ratio10.42x
Interest coverage-4.69x

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-2.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$233,000$270,000$669,000$3.50M$9.13M$6.74M$5.37M$1.10M
SG&A expense$5.83M$5.71M$5.97M$6.06M$6.34M$6.16M$9.11M$10.37M
Operating income-$5.99M-$6.16M-$7.63M-$9.56M-$15.47M-$23.44M-$30.56M-$11.82M
Interest expense$1.55M$1.58M$1.55M$1.57M$1.58M$1.58M$1.10M$3.00M
Net income-$4.23M-$4.42M-$4.37M-$8.19M-$13.59M-$21.39M-$28.51M-$11.89M
EBITDA-$5.29M-$5.96M-$7.62M-$9.54M-$15.46M-$23.44M-$30.06M-$11.08M
EPS (basic)-0.62-0.65-0.64—-2.01-3.24-4.32—
EPS (diluted)-0.62-0.65-0.64—-2.01-3.24-4.32—
Weighted avg. shares (diluted)6.78M6.78M6.78M—6.76M6.60M6.53M—
Balance sheet
Cash & equivalents$2.54M$5.54M$5.02M$6.64M$6.08M$7.84M$16.33M$10.63M
Short-term investments$59.53M——$69.49M————
Current assets$65.51M$73.11M$189.67M$192.42M$196.26M$207.39M$219.26M$124.47M
PP&E, net$111.10M$111.78M$112,000$126,000$138,000$150,000$162,000$129.41M
Total assets$195.65M$199.22M$201.80M$204.51M$211.77M$230.99M$237.45M$263.57M
Current liabilities$6.29M$6.29M$7.46M$7.03M$5.70M$13.85M$7.23M$7.90M
Total liabilities$93.08M$93.32M$92.46M$91.84M$91.35M$99.32M$92.54M$94.13M
Shareholders' equity$102.56M$105.90M$109.34M$112.67M$118.94M$130.19M$143.43M$168.27M
Shares outstanding6.78M6.78M6.78M6.78M6.78M6.75M6.56M6.53M
Cash flow statement
Operating cash flow-$2.40M-$4.64M-$1.34M-$7.08M-$10.56M-$14.79M-$4.20M-$10.56M
Capital expenditure———————$0
Free cash flow———————-$10.56M
Investing cash flow-$155,000$5.29M-$317,000$7.82M$8.45M-$400,000$9.61M$13.00M
Financing cash flow-$300,000$0$0$0$378,000$6.68M$232,000$1.60M
Depreciation & amortization$700,000$200,000$12,000$12,000$10,000$0$498,000$741,000
Stock-based compensation$984,000$1.04M$985,000$1.61M$1.77M$1.82M$3.50M$4.50M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.